N4 Pharma Share Discussion Threads

[backtogo] 03/7/2017 15:28

going under ipo price this one.. be careful

[whl2] 03/7/2017 12:58

We have already demonstrated its transfection capability compared to standard industry in vitro techniques (lipofectamine) and it is important we undertake studies to further show we can achieve transfection in an in vivo environment. Whilst there remain several important steps before we can demonstrate the suitability of our nuvec(R) system to our potential commercial partners, the fact that we can show there is no systemic toxicity is a very important hurdle to overcome.

Can't see Nuvec ready to go in October zebbo, rns suggests more trials lie ahead. Still a great company though, will add more when funds become available, eg pay day!

[zebbo] 03/7/2017 12:21

Hi folks, I'm now 5 figures under water, but actually quiet relaxed and trust my research and the exceptional BOD. Slightly annoyed at getting my timing wrong though. Should have waited until people lost interest, but did not want to miss the boat with N4P, particularly after my research. However.....

Near term a possible commercial deal for Nuvec which should be available for the pharma industry ~Oct time frame, this has massive potential and not surprised it is number 1 focus.
Plus FDA sign off for Sildenafil 2018 following clinical trails
++more patent news flow / opportunities

[zebbo] 03/7/2017 12:21

Hi folks, I'm now 5 figures under water, but actually quiet relaxed and trust my research and the exceptional BOD. Slightly annoyed at getting my timing wrong though. Should have waited until people lost interest, but did not want to miss the boat with N4P, particularly after my research. However.....

Near term a possible commercial deal for Nuvec which should be available for the pharma industry ~Oct time frame, this has massive potential and not surprised it is number 1 focus.
Plus FDA sign off for Sildenafil 2018 following clinical trails
++more patent news flow / opportunities

[bones] 03/7/2017 10:16

sep800. OK thanks.

The PCT I believe is the standard method for ensuring patents get filed in as many countries as possible in one go. It is still the case that each of the individual patent applications gets to be dealt with individually by each country's patent registering authorities, so we are looking at a long process for the patents to be accepted worldwide (I think).

[sep800] 03/7/2017 02:00

Yes Bones, Just reminding everyone the patents were filled prior to the latest RNS which confirms progress is very positive.
They now have a proven formula, watch large pharmaceutical interested in their patents for licensing and no one else can other these.

[bones] 03/7/2017 01:22

sep800, that RNS was released on 15th May.

[sep800] 03/7/2017 00:56

Sildenafil Update

Since the start of this year, work has continued on the Company's sildenafil reformulation and the Company has now filed its PCT patent application seeking worldwide protection of the Company's reformulation methodology. This follows the successful completion of the laboratory dissolution testing of the formulation to establish the correct dissolution profile required for the reformulated product.

[parob] 30/6/2017 07:43

A step in the right direction...

[someuwin] 30/6/2017 07:09

June 2017

N4 Pharma Plc

("N4 Pharma" or the "Company")

Update on toxicity testing of nuvec(R) particles

N4 Pharma Plc (AIM: N4P), a specialist pharmaceutical company which reformulates existing drugs and vaccines to improve their performance, is pleased to announce the latest research results for its nuvec(R) nanoparticles which it is developing as a delivery system for DNA and mRNA vaccines and therapeutics.

Toxicity Study Results

The objective of this study (funded via a biomedical Catalyst grant) was to assess the systemic tolerability of the nuvec(R) Silica nanoparticles when administered as a single dose via subcutaneous injection to rats, a standard non-clinical species for such studies.

Animals were dosed once with 50, 150, 400 or 900 mg/kg nanoparticles, and then observed for 14 days. Clinical observations, body weights and food consumption were recorded, blood plasma samples were analysed for clinical pathology and selected common target organs were examined microscopically.

The nanoparticles did not cause any systemic toxicity and all organs examined microscopically were normal, including at the highest dose, which is likely to be many times in excess of the concentrations that might be administered to humans. While there was some mild to moderate inflammation observed at the injection sites at all doses, these were non-specific and generally indicative of local inflammation.

According to the board certified pathologist used in the study, these were similar to that which would be expected following implantation of a medical device or as a result of injecting a vaccine and would almost certainly resolve over time.

In conclusion, a single subcutaneous administration of the nuvec(R) nanoparticles to rats did not cause any toxicological effects considered likely to be of long term concern.

ApconiX Limited, the Company's partners in these studies, have approved this as an accurate reflection of the results observed.

Following these results, further in vivo studies to demonstrate the transfection capability of the Company's nuvec(R) particles will be performed.

Nigel Theobald, CEO of N4 Pharma, commented:

"We continue to make good progress demonstrating the capability of our nuvec(R) vaccine delivery system.

We have already demonstrated its transfection capability compared to standard industry in vitro techniques (lipofectamine) and it is important we undertake studies to further show we can achieve transfection in an in vivo environment. Whilst there remain several important steps before we can demonstrate the suitability of our nuvec(R) system to our potential commercial partners, the fact that we can show there is no systemic toxicity is a very important hurdle to overcome.

We will provide further updates as each step of the program develops."

[parob] 28/6/2017 22:02

Grabbed a few more at 8.5p today - was amazed at the price (and market cap) and couldn't resist some more. Whilst in a different space, anyone who has followed the OPTI story will appreciate how undervalued this is with potential news that could land on so many fronts. All in huge markets. That's why I like this share - like OPTI it isn't a 'one trick pony'. This will turn soon enough and when it does I'm expecting the reversal to be pretty quick. We'll be grateful we had the opportunity to build a position at this price IMO.

[bones] 28/6/2017 19:52

Zebbo, close to 0.5% myself across 3 accounts!

[zebbo] 28/6/2017 19:32

With you there bones and yes volsung 8p is a great price. Think my Av is nearer 10p, but more than happy even at 10p.

As a 0.5% shareholder Im more than fully invested on this one

[volsung] 28/6/2017 11:51

8p is a good price to buy in here

[bones] 28/6/2017 11:49

In, out, shake it all about!

I'm holding very firm here. I wish I could buy more at these prices!

[moormoney] 23/6/2017 13:51

I've topped up ready for next week. If there's a scramble for shares....fingers crossed!

[moormoney] 23/6/2017 11:41

Definitely looks as though good news is coming..leaky leaky!!!

[patientcapital] 23/6/2017 11:23

And upwards :)

[ch1rp] 23/6/2017 11:19

Back to 12p then onwards:)))

[someuwin] 23/6/2017 09:45

News on Sildenafil clinical trials soon imo.

[nesty1760] 22/6/2017 13:25

I think next week people going to be all over this!
On many peoples radars now. Also some twitter people who have a large followings taking notice.
Could see this push past 15p next week!

[westmoreland lad] 22/6/2017 13:09

moving up on every tiny purchase. Looks like all buys since breakfast.

[nesty1760] 22/6/2017 12:54

Whoever got in at sub 9 very well done. Total steal at these prices!

Can see this at 15p in the short period

[someuwin] 22/6/2017 12:34

Moving up.

[someuwin] 20/6/2017 14:55

Sensible peeps buying the dips.